Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rises up 21.21% to close at $37.89 with the total traded volume of 14.82 Million. The firm’s current ratio calculated as 6.70 for the most recent quarter Sarepta Therapeutics (SRPT) disclosed entry into two contracts with the Nationwide Children’s Hospital. The co has entered an exclusive license contract with Nationwide Children’s Hospital, for their Galgt2 gene therapy program developed by researcher Dr. Paul Martin, Ph.D. The experimental program explores the potential surrogate gene therapy approach to Duchenne muscular dystrophy.
“Our goal is to have this program in the clinic during 2017 and begin to evaluate a therapy that has the potential to treat patients of all ages and disease severity.”The co also has entered a research and option contract with Nationwide Children’s Hospital on their microdystrophin gene therapy program. Dr. Jerry Mendell, M.D. and Dr. Louise Rodino-Klapac, Ph.D., are the lead principal investigators of the program.
The initial trial, expected to go into Phase 1/2a trial in late 2017, will be conducted at Nationwide Children’s. Parent Project Muscular Dystrophy has committed 2.2 million dollars to the trial, with support from additional Duchenne foundations and families. Sarepta has committed to the trial through a separate research contract with Nationwide Children’s, and has an exclusive option to license the program. PPMD’s grant provided incentive for Sarepta to help expand and accelerate this opportunity.
Can Sarepta Therapeutics, Inc. breaks its Bearish streak After this ratings upgrade? Find Out Here
Shares of Lamb Weston Holdings, Inc. (NYSE:LW) has price volatility of 3.48% in last 5 days trading session, while shares of firm closed at $36.84 are decreasing -0.14% in last session. Lamb Weston Holdings, Inc. (LW) reported that its second quarter 2017 results. Net sales were $791 million, up 7 percent versus the year-ago period. Volume surged 4 percentage points as productivity programs and strong manufacturing plant performance stretched accessible capacity, allowing the Company to meet demand growth in both North America and international markets.
Price/mix surged 3 percentage points due to pricing actions and favorable product and consumer mix.Income from operations surged 15 percent to $126 million from $110 million in the prior year period, and included $9 million of costs related to the spinoff from Conagra Brands, Inc. Shares price moving up from its 20 days moving average with 1.33% and isolated positively from 50 days moving average with 5.87%.
How Lamb Weston Holdings, Inc. tops analyst’s views after bullish guidance? Find Out Here
Stocks of Perrigo Company plc (NYSE:PRGO) shows active performance, collapsed -2.08% to trade at $83.65as Perrigo (PRGO) plans to change reporting sections beginning in Q4 – will have no impact on historical results. The firm changes its reporting sections to better align with its organizational structure. Beginning with the Q4, its new reporting sections are- Consumer Healthcare Americas, Comprises the legacy US, Mexico and Canada consumer healthcare business (OTC, contract, infant formula and animal health categories).
Consumer Healthcare International, Comprises the legacy Branded Consumer Healthcare section and now includes its consumer focused businesses in the UK Australia and Israel, which were previously declared in the legacy Consumer Healthcare section.
Most exciting investors analysis over PRGO performance this year? Find Out Here Totally Free